Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass., June 4, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be combined with standard doses of certain cytotoxic agents for investigation as treatment for patients with advanced solid tumors. The research was presented at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, May 31 – June 4, 2013.
Help employers find you! Check out all the jobs and post your resume.
